Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.

Laboratory investigation; a journal of technical methods and pathology - 1 Feb 2017

Hartman Mariusz L, Rozanski Michal, Osrodek Marta, Zalesna Izabela, Czyz Malgorzata

Abstract excerpt

Clinical evidence has revealed that while RAS/RAF/MEK/ERK pathway is a crucial component of melanomagenesis, other signaling pathways can also contribute to the malignant growth and development of resistance to targeted therapies. We explored the response of V600EBRAF melanoma cells derived from surgical specimens and grown in stem cell medium to vemurafenib and trametinib, drugs targeting the activity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Connective Tissue Growth Factor
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Interleukin-8

Share to Pyridones

Share to Pyrimidinones

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 28067893
DOI: 10.1038/labinvest.2016.140

Genes

CCND1
BRAF
CXCL8
DKK1
MITF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.PMID 28067893Read ↗

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.Semantic proximity Read ↗

BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.Semantic proximity Read ↗

A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.Semantic proximity Read ↗

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.Semantic proximity Read ↗

A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanomaSemantic proximity Read ↗

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutatedSemantic proximity Read ↗

Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.Semantic proximity Read ↗

Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.Semantic proximity Read ↗

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.